9-cyclopropyl-6,7-difluoro-8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-dione | 922491-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-cyclopropyl-6,7-difluoro-8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-dione
• 英文别名: 9-Cyclopropyl-6,7-difluoro-8-methoxyisothiazolo[5,4-b]quinoline-3,4(2h,9h)-dione；9-cyclopropyl-6,7-difluoro-8-methoxy-[1,2]thiazolo[5,4-b]quinoline-3,4-dione
• CAS: 922491-07-4
• 化学式: C₁₄H₁₀F₂N₂O₃S
• 分子量: 324.308
• InChiKey: JANMPUDRRSDTFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  83.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  9-cyclopropyl-6,7-difluoro-8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-dione 在 四(三苯基膦)钯 亚硝酸特丁酯 、 碳酸氢钠 、 copper(ll) bromide 作用下， 以 二氯甲烷 、 N,N-二甲基乙酰胺 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 30.5h， 生成 9-cyclopropyl-7-(2,6-dimethyl-pyridin-4-yl)-6-fluoro-8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-dione
  参考文献：
  名称：

  Isothiazoloquinolones with Enhanced Antistaphylococcal Activities against Multidrug-Resistant Strains:  Effects of Structural Modifications at the 6-, 7-, and 8-Positions

  摘要：

  We describe the biological evaluation of isothiazoloquinolones (ITQs) having structural modifications at the 6-, 7-, and 8-positions. Addition of a methoxy substituent to C-8 effected an increase in antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and a decrease in cytotoxic activity against Hep2 cells. Removal of fluorine from C-6 or replacement of the C-8 carbon with a nitrogen compromised anti-MRSA activity. When the groups attached at C-7 were compared, the anti-MRSA activity decreased in the order 6-isoquinolinyl > 4-pyridinyl > 5-dihydroisoindolyl > 6-tetrahydroisoquinolinyl. The compound with the most desirable in vitro biological profile was 9-cyclopropyl-6-fluoro-8-methoxy-7-(2-methylpyridin-4-yl)-9H-isothiazolo[5,4-b]quinoline-3,4-dione (7g). This ITQ demonstrated (i) strong in vitro anti-MRSA activity (MIC90 = 0.5 mu g/mL), (ii) strong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities against three cell lines, and (iv) efficacy in an in vivo murine thigh model of infection employing MRSA.

  DOI：

  10.1021/jm060844e
• 作为产物：
  描述：

  3-氧代-3-(2,4,5-三氟-3-甲氧基苯基)-丙酸乙酯 在 Oxone 、 potassium phosphate 、 sodium hydrosulfide hydrate 、 potassium tert-butylate 、 四丁基溴化铵 、 potassium hydroxide 、 hydroxylamine-O-sulfonic acid 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 43.5h， 生成 9-cyclopropyl-6,7-difluoro-8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-dione
  参考文献：
  名称：

  强大的广谱抗菌异噻唑并喹诺酮的实用合成与分子结构

  摘要：

  我们报道了新的2-磺酰基喹诺酮乙基1-环丙基-6,7-二氟-2-甲磺酰基-8-甲氧基-4-氧代-1,4-二氢喹啉-3-羧酸酯的合成（5）。砜5是在isothiazoloquinolone 9-环丙基-6-氟-8-甲氧基-7-（2-甲基-吡啶-4-基）-9-的优化合成中使用的关键中间体ħ -isothiazolo并[5,4- b ]喹啉-3,4-dione（1），一种有效的广谱抗菌剂，对临床上重要的耐药生物（例如耐甲氧西林的金黄色葡萄球菌（MRSA））有效。我们的合成方法无需色谱纯化，可进行大规模合成。1的分子结构，9-环丙基-6,7-二氟-8-甲氧基-9 H-异噻唑并[5,4 - b ]喹啉-3,4-二酮（4），5和乙基2-环丙基氨基-6,7-二氟使用多核NMR光谱学和X射线晶体学方法明确地建立了-8-甲氧基-4-氧代-4 H-硫代亚甲基-3-羧酸盐（10）。

  DOI：

  10.1021/op700014t

文献信息

• 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
  申请人：Bradbury James Barton

  公开号：US20070049586A1

  公开（公告）日：2007-03-01

  The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: Such compounds possess useful antimicrobial activity. The variables R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 shown in Formula A and B are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

  本发明提供了公式I和II的化合物和盐，其中包括公式A和公式B的化合物：这些化合物具有有用的抗微生物活性。公式A和B中显示的变量R2、R3、R5、R6、R7和R9在此定义。本文所披露的公式I和公式II的某些化合物是强效和/或选择性的细菌DNA合成和细菌复制抑制剂。本发明还提供了抗微生物组合物，包括含有公式I或公式II中一个或多个化合物和一个或多个载体、赋形剂或稀释剂的制药组合物。这些组合物可以仅包含公式I或公式II中的一个化合物作为唯一活性剂，也可以包含公式I或公式II中的一个化合物和一个或多个其他活性剂的组合物。本发明还提供了治疗动物微生物感染的方法。
• 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS
  申请人：Bradbury Barton James

  公开号：US20120040959A1

  公开（公告）日：2012-02-16

  The invention provides compound and salts of Formula I and II, disclosed herein, which includes compounds of Formula A and Formula B: Such compounds possess useful antimicrobial activity. The variables R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 shown in Formula A and B are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

  本发明提供了公式I和II的化合物和盐，其中包括公式A和公式B的化合物：这些化合物具有有用的抗微生物活性。 公式A和B中显示的变量R2、R3、R5、R6、R7和R9在此定义。 本文所披露的某些公式I和公式II的化合物是细菌DNA合成和细菌复制的有效和/或选择性抑制剂。 本发明还提供了抗微生物组合物，包括含有一个或多个公式I或公式II化合物的制药组合物和一个或多个载体、赋形剂或稀释剂。 这样的组合物可以仅包含公式I或公式II的化合物作为唯一活性剂，也可以包含公式I或公式II的化合物和一个或多个其他活性剂的组合物。 本发明还提供了治疗动物微生物感染的方法。
• Exploration of the Activity of 7-Pyrrolidino-8-methoxyisothiazoloquinolones against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA)
  作者：Ha Young Kim、Jason A. Wiles、Qiuping Wang、Godwin C. G. Pais、Edlaine Lucien、Akihiro Hashimoto、David M. Nelson、Jane A. Thanassi、Steven D. Podos、Milind Deshpande、Michael J. Pucci、Barton J. Bradbury

  DOI：10.1021/jm101604v

  日期：2011.5.12

  A series of 7-(3'-substituted)pyrrolidino-8-methoxyisothiazoloquinolone (ITQ) analogues were prepared, and their antibacterial potency against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and Escherichia coli were compared. Many of these analogues had MIC <= 0.25 mu g/mL against quinolone-resistant MRSA strains. The stereochemical preference was explored for a series of 1 ''-methyl-3'-aminomethylpyrrolidine analogues. Antibacterial activity was generally more favorable with 3'-R, 1 ''-S configuration. Substitution on the 3'-aminomethyl nitrogen tended to decrease activity, while potency was maintained with disubstitution or aryl substitution at the 1 ''-carbon. The 7-[(R)-3-((S)-1-aminoethyl)pyrrolidin-1-yl] analogue (6a(R,S)) and the (R)-7-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl] analogue (7a(R)) were found to be the ITQs with the most promising antibacterial profiles. The MICs of these select ITQs versus a panel of clinical MRSA strains were determined, and the ITQs were found to have 8- to 16-fold greater potency than linezolid. These analogues were also evaluated for inhibition of the target enzymes, topoisomerase IV and DNA gyrase, from both wild-type and multidrug resistant strains. The ITQs were up to >30 times more inhibitory against these targets than the fluoroquinolone moxifloxacin.
• WO2007/14308
  申请人：——

  公开号：——

  公开（公告）日：——
• US8044204B2
  申请人：——

  公开号：US8044204B2

  公开（公告）日：2011-10-25